High frequency of HLA-B44 allelic losses in human solid tumors

Human Immunology

Volumn 64, Issue 10, 2003, Pages 941-950

  Cabrera, Teresa ^a   Maleno, Isabel ^a   Lopez Nevot, Miguel Angel ^a   Redondo, Maximino ^b   Fernandez, Maria Angustias ^a   Collado, Antonia ^a   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

Author keywords

Expression; HLA; HLA B44; LOH; Tumor

Indexed keywords

DNA; HLA B ANTIGEN; HLA B44 ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FROZEN SECTION; GENE FREQUENCY; GENE LOSS; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MOLECULAR RECOGNITION; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY;

EID: 0141642048     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(03)00164-2     Document Type: Article

References (45)

1. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL: Natural history of HLA expression during tumour development. Immunol Today 14:491, 1993.
2. Bodmer WF, Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG: Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann N Y Acad Sci 690:42, 1993.
3. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18:89, 1997.
4. Kaklamanis L, Hill A: MHC loss in colorectal tumours: evidence for immunoselection? Cancer Surv 13:155, 1992.
5. Garrido F: HLA and cancer. Tissue Antigens 47:361, 1996.
6. Tomlinson I, Bodmer W: Selection, the mutation rate and cancer: ensuring that the tail does not wag the dog. Nat Med 5:11, 1999.
7. Garcia-Lora A, Algarra I, Gaforio JJ, Ruiz-Cabello F, Garrido F: Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants. Int J Cancer 91:109, 2001.
8. Garrido F, Algarra I: MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 83:117, 2001.
9. Marin R, Ruiz-Cabello F, Pedrinaci S, Mendez R, Geraghty E, Garrido F: Analysis of HLA-E expression in human tumors. Immunogenetics 54:767, 2003.
10. Garrido F, Cabrera T, Accolla RS, Bensa JC, Bodmer W, Dohr G, Drenou B, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola F, Mazzilli C, Morel PA, Murray A, Papasteriades C, Salvaneschi L, Stern PL, Uchanska-Ziegler B: HLA and cancer. In: Charron D (ed): HLA, Genetic Diversity of HLA: Functional and Medical Implications, Volume 1. Paris: EDK, 1997.
11. Arnaiz-Villena A, Rodriguez de Cordoba S, Vela F, Pascual JC, Cervero J, Bootello A: HLA antigens in a sample of the Spanish population: common features among Spaniards, Basques, and Sardinians. Hum Genet 58:344, 1981.
12. Cabrera T, Lopez-Nevot MA, Gaforio JJ, Ruiz-Cabello F, Garrido F: Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother 52:1, 2003.
13. Cabrera T, Fernandez MA, Sierra A, Garrido A, Herruzo A, Escobedo A, Fabra A, Garrido F: High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50:127, 1996.
14. Ramal LM, Maleno I, Cabrera T, Collado A, Ferron A, Lopez-Nevot MA, Garrido F: Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum Immunol 61:1001, 2000.
15. Tamiya G, Shiina T, Oka A, Tomizawa M, Ota M, Katsuyama Y, Yoshitome M, Makino S, Kimura M, Inoko H: New polymorphic microsatellite markers in the human MHC class I region. Tissue Antigens 54:221, 1999.
16. Ramal LM, Feenstra M, van der Zwan AW, Collado A, Lopez-Nevot MA, Tilanus M, Garrido F: Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens 55:443, 2000.
17. Maleno I, Lopez-Nevot A, Cabrera T, Salinero J, Garrido F: Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunol Immunother 51:389, 2002.
18. Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S: Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. Cancer Res 58:2149, 1998.
19. Serrano A, Brady CS, Jimenez P, Duggan-Keen MF, Mendez R, Stern P, Garrido F, Ruiz-Cabello F: A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells. Immunogenetics 51:1047, 2000.
20. Versteeg R, Noordermeer IA, Kruse-Wolters M, Ruiter DJ, Schrier PI: C-myc down-regulates class I HLA expression in human melanomas. EMBO J 7:1023, 1988.
21. Nouri AM, Symes MO: Relevance of the immune system in human urological malignancies: prospective for future clinical treatments. Urology 51(Suppl):41, 1998.
22. Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC: Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol 145:505, 1994.
23. Vora AR, Rodgers S, Parker AJ, Start R, Rees RC, Murray AK: An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer 76:836, 1997.
24. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B: Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19:1211, 2001.
25. Matsui M, Ikeda M, Akatsuka T: High expression of HLA-A2 on an oral squamous cell carcinoma with downregulated transporter for antigen presentation. Biochem Biophys Res Commun 280:1008, 2001.
26. Lewis JW, Sewell A, Price D, Elliott T: HLA-A*0201 presents TAP-dependent peptide epitopes to cytotoxic T lymphocytes in the absence of tapasin. Eur J Immunol 28:3214, 1998.
27. Ortmann B, Copeman J, Lehner PJ, Sadasivan B, Herberg JA, Grandea AG, Riddell SR, Tampe R, Spies T, Trowsdale J, Cresswell P: A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 277:1306, 1997.
28. Peh CA, Burrows SR, Barnden M, Khanna R, Cresswell P, Moss DJ, McCluskey J: HLA-B27-restricted antigen presentation in the absence of tapasin reveals polymorphism in mechanisms of HLA class I peptide loading. Immunity 8:531, 1998.
29. Peh CA, Laham N, Burrows SR, Zhu Y, McCluskey J: Distinct functions of tapasin revealed by polymorphism in MHC class I peptide loading. J Immunol 164:292, 2000.
30. Luckey CJ, Marto JA, Partridge M, Hall E, White FM, Lippolis JD, Shabanowitz J, Hunt DF, Engelhard VH: Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors. J Immunol 167:1212, 2001.
31. Reber AJ, Turnquist HR, Thomas HJ, Lutz CT, Solheim JC: Expression of invariant chain can cause an allele-dependent increase in the surface expression of MHC class I molecules. Immunogenetics 54:74, 2002.
32. Gotch F, Rothbard J, Howland K, Townsend A, McMichael A: Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 326:881, 1987.
33. Ellis JR, Keating PJ, Baird J, Hounsell EF, Renouf DV, Rowe M, Hopkins D, Duggan-Keen MF, Bartholomew JS, Young LS, et al: The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nat Med 1:464, 1995.
34. Bontkes HJ, Walboomers JM, Meijer CJ, Helmerhorst TJ, Stern PL: Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 351:187, 1998.
35. Perez-Ayala M, Ruiz-Cabello F, Esteban F, Concha A, Redondo M, Oliva MR, Cabrera T, Garrido F: Presence of HPV 16 sequences in laryngeal carcinomas. Int J Cancer 46:8, 1990.
36. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25:340, 1995.
37. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA: Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88:100, 1996.
38. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A: Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71:142, 1997.
39. Schreiber H, Wu TH, Nachman J, Kast WM: Immunodominance and tumor escape. Semin Cancer Biol 12:25, 2002.
40. Boon T, Old LJ: Cancer tumor antigens. Curr Opin Immunol 9:681, 1997.
41. Jager E, Jager D, Knuth A: Clinical cancer vaccine trials. Curr Opin Immunol 14:178, 2002.
42. Fleischhauer K, Fruci D, Van Endert P, Herman J, Tanzarella S, Wallny HJ, Coulie P, Bordignon C, Traversari C: Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3. Int J Cancer 68:622, 1996.
43. Herman J, van der Bruggen P, Luescher IF, Mandruzzato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG: A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogenetics 43:377, 1996.
44. Chiari R, Foury F, De Plaen E, Baurain JF, Thonnard J, Coulie PG: Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res 59:5785, 1999.
45. Dolstra H, Fredrix H, Maas F, Coulie PG, Brasseur F, Mensink E, Adema GJ, de Witte TM, Figdor CG, van de Wiel-van Kemenade E: A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 189:301, 1999.